CD274 and neoplasm: PD-L1 expression on tumor cells (≥1% vs. <1%/indeterminate) was a stratification factor in the PIVOT IO 001 trial9, so the association between tumor cell PD-L1 expression, measured at the screening visit, and efficacy in the BEMPEG + NIVO versus NIVO treatment arm was examined (see “Methods”).